epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002 Feb;59(2):205-10. \[[PubMed: 11843690](https://pubmed.ncbi.nlm.nih.gov/11843690)\] 6. Strzelczyk A, Ansorge S, Hapfelmeier J, Bonthapally V, Erder MH, Rosenow F. Costs, length of stay, and mortality of super-refractory status epilepticus: A population-based study from Germany. Epilepsia. 2017 Sep;58(9):1533-1541. \[[PubMed: 28681418](https://pubmed.ncbi.nlm.nih.gov/28681418)\] 7. Delaj L, Novy J, Ryvlin P, Marchi NA, Rossetti AO. Refractory and super-refractory status epilepticus in adults: a 9-year cohort study. Acta Neurol Scand. 2017 Jan;135(1):92-99. \[[PubMed: 27080243](https://pubmed.ncbi.nlm.nih.gov/27080243)\] 8. Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012 Aug;135(Pt 8):2314-28. \[[PubMed: 22577217](https://pubmed.ncbi.nlm.nih.gov/22577217)\] 9. Wilder-Smith EP, Lim EC, Teoh HL, Sharma VK, Tan JJ, Chan BP, Ong BK. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singap. 2005 Aug;34(7):417-20. \[[PubMed: 16123813](https://pubmed.ncbi.nlm.nih.gov/16123813)\] 10. Hirsch LJ, Gaspard N, van Baalen A, Nabbout R, Demeret S, Loddenkemper T, Navarro V, Specchio N, Lagae L, Rossetti AO, Hocker S, Gofton TE, Abend NS, Gilmore EJ, Hahn C, Khosravani H, Rosenow F, Trinka E. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia. 2018 Apr;59(4):739-744. \[[PubMed: 29399791](https://pubmed.ncbi.nlm.nih.gov/29399791)\] 11. Gaspard N, Foreman BP, Alvarez V, Cabrera Kang C, Probasco JC, Jongeling AC, Meyers E, Espinera A, Haas KF, Schmitt SE, Gerard EE, Gofton T, Kaplan PW, Lee JW, Legros B, Szaflarski JP, Westover BM, LaRoche SM, Hirsch LJ., Critical Care EEG Monitoring Research Consortium (CCEMRC). New-onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology. 2015 Nov 03;85(18):1604-13. \[[PMC free article: PMC4642147](/pmc/articles/PMC4642147/)\] \[[PubMed: 26296517](https://pubmed.ncbi.nlm.nih.gov/26296517)\] 12. Rahman S. Mitochondrial diseases and status epilepticus. Epilepsia. 2018 Oct;59 Suppl 2:70-77. \[[PubMed: 30159903](https://pubmed.ncbi.nlm.nih.gov/30159903)\] 13. Husari KS, Labiner K, Huang R, Said RR. New-Onset Refractory Status Epilepticus in Children: Etiologies, Treatments, and Outcomes. Pediatr Crit Care Med. 2020 Jan;21(1):59-66. \[[PubMed: 31568262](https://pubmed.ncbi.nlm.nih.gov/31568262)\] 14. Kramer U, Chi CS, Lin KL, Specchio N, Sahin M, Olson H, Nabbout R, Kluger G, Lin JJ, van Baalen A. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia. 2011 Nov;52(11):1956-65. \[[PubMed: 21883180](https://pubmed.ncbi.nlm.nih.gov/21883180)\] 15. Gaspard N, Hirsch LJ, Sculier C, Loddenkemper T, van Baalen A, Lancrenon J, Emmery M, Specchio N, Farias-Moeller R, Wong N, Nabbout R. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia. 2018 Apr;59(4):745-752. \[[PubMed: 29476535](https://pubmed.ncbi.nlm.nih.gov/29476535)\] 16. van Baalen A, Vezzani A, HÃ¤usler M,